Comparison of Efficacy in Removal of Advanced Glycation End Products (AGEs) Between Super High-flux Hemodialysis and Postdilution Online Hemodiafiltration: A Single-center, Prospective, Open-label, Crossover Randomized Controlled Trial - Trial NCT05777148
Access comprehensive clinical trial information for NCT05777148 through Pure Global AI's free database. This phase not specified trial is sponsored by Mahidol University and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mahidol University
Timeline & Enrollment
N/A
Apr 04, 2022
Jun 30, 2023
Primary Outcome
skin autofluorescence for AGEs
Summary
The goal of this clinical trial is to compare efficacy in advanced glycation end products
 removal between Super high-flux Hemodialysis and high-volume post-dilution online
 hemodiafiltration. The main question it aims to answer are
 
 - Efficacy : endothelial dysfunction biomarker (AGEs) in super high-flux hemodialysis
 compared to online HDF
 
 - Safety profile : Dialysate albumin loss, Intradialytic complication
 
 Participants will be asked to randomized in 2 groups : Super high-flux HD or post dilution
 ol-HDF Researchers will compare SHF-HD and ol-HDF to see whether SHF-HD could remove AGEs
 better than ol-HDF
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05777148
Device Trial